<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455985</url>
  </required_header>
  <id_info>
    <org_study_id>2017H0354</org_study_id>
    <nct_id>NCT03455985</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin</brief_title>
  <official_title>Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is present in 25% of hospitalized patients; yet effective hospital discharge
      programs for patients with diabetes are understudied. In particular, patients who are
      initiating or intensifying insulin therapy have the most to benefit in terms of glycemic
      control. However, these patients are also particularly vulnerable to poor transitions of care
      for a variety of reasons, including the complexity of therapy, inadequate patient education,
      differences in patient and provider expectations, and insufficient resources. Disruption of
      insulin therapy following hospitalization is associated with higher HbA1c, shorter survival,
      and increased readmissions and medical costs. In a Society of Hospital Medicine Survey, only
      one fourth of hospitals were supported with written protocols to standardize medication,
      education, equipment, and follow-up instructions. However, discharge order sets have largely
      been limited to the inpatient setting and have not been utilized to guide insulin use at
      hospital discharge. This study will assess whether a nurse supported diabetes focused
      inpatient discharge order set (DOS) can improve post-discharge outcomes among hospitalized
      patients with poorly controlled insulin-requiring diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this 24 week randomized controlled trial, hospitalized insulin-requiring patients with
      type 2 diabetes and poor glycemic control (HbA1c &gt;8.5%) will receive standard of care insulin
      therapy including basal insulin glargine U300 (TOUJEO®) plus additional background therapy
      (non-insulin and prandial insulin therapies) with either a diabetes focused discharge order
      set (DOS) and follow-up communication to facilitate insulin titration and outpatient
      follow-up or enhanced standard care (ESC). 222 patients (type 2 diabetes) will be recruited.
      Hospitalized patients with type 2 diabetes (HbA1c &gt;8.5%) who are receiving basal insulin at
      least 10 unit per day and are able to provide informed consent and complete study procedures
      will be approached. All patients will be discharged on glargine U300 with initial doses
      determined by the discharging team. Patients in the DOS group will receive instructions for
      self-titration of basal insulin as part of the discharge order. The DOS contains a
      comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions
      for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders.
      Patients will have follow-up phone calls at week 2, 6, and in-person visits at week 12 and
      24. Phone calls will assess adherence with instructions for self-titration in the DOS group
      but are information gathering only in the ESC group, and questions related to care will be
      referred to the usual provider. Glucose lowering medication management following discharge
      will otherwise be conducted by the patient's usual or designated standard of care provider.
      The study and all study-related documents will be approved by the OSU IRB. All data analyses
      will be completed as intention to treat analyses. Longitudinal outcomes (e.g., HbA1c) will be
      analyzed using mixed models utilizing all available measurements from individuals randomized.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>We will test for a difference in 24 week change in HbA1c between the DOS and ESC groups using a linear mixed model for the longitudinal HbA1c measurements. A Wald test of the treatment-by-time interaction will be used to test our primary hypothesis that DOS affects 24 weeks change in Hb1Ac.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will test for a difference in 24 week change in HbA1c between the DOS and ESC groups using a linear mixed model for the longitudinal HbA1c measurements. A Wald test of the treatment-by-time interaction will be used to test our primary hypothesis that DOS affects 12 weeks change in Hb1Ac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence with insulin therapy.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The difference in proportions between treatment groups will be computed and compared using test of proportions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>24 weeks</time_frame>
    <description>We will test for a difference in 24 week change in fasting glucose between the DOS and ESC groups using a linear mixed model for the longitudinal HbA1c measurements. A Wald test of the treatment-by-time interaction will be used to test our primary hypothesis that DOS affects 24 weeks change in Hb1Ac.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Patient Discharge</condition>
  <condition>Blood Glucose, Low</condition>
  <condition>Blood Glucose, High</condition>
  <arm_group>
    <arm_group_label>Discharge Order Set (DOS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Standard Care (ESC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discharge Order Set (DOS)</intervention_name>
    <description>In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.</description>
    <arm_group_label>Discharge Order Set (DOS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enhanced Standard Care (ESC)</intervention_name>
    <description>Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.</description>
    <arm_group_label>Enhanced Standard Care (ESC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes, type 2 ≥3 months duration

          -  HbA1c &gt;8.5%

          -  Ages 25-75 years

          -  Phone or electronic media availability

          -  Receiving basal insulin &gt;10 unit/day

        Exclusion Criteria:

          -  Sensitive admissions: Prisoners

          -  Pregnancy

          -  Unable to consent or follow study directions in English

          -  Expected nursing facility stay longer than 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Dungan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob E LaFleur, BA</last_name>
    <phone>6146886262</phone>
    <email>jacob.lafleur@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Howell, LPN</last_name>
    <phone>6146883785</phone>
    <email>angela.howell@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob E LaFleur, BA</last_name>
      <phone>614-688-6262</phone>
      <email>jacob.lafleur@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Howell, LPN</last_name>
      <phone>6146883785</phone>
      <email>angela.howell@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Dungan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwame Osei, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Buscher, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cara Harris, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Bradley, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://archive.ahrq.gov/data/hcup/highlight1/high1.pdf</url>
    <description>Healthcare Cost and Utilization Project. Economic and Health Costs of Diabetes</description>
  </link>
  <link>
    <url>http://products.sanofi.us/toujeo/toujeo.pdf</url>
    <description>Toujeo prescribing instructions</description>
  </link>
  <reference>
    <citation>Cook CB, Seifert KM, Hull BP, Hovan MJ, Charles JC, Miller-Cage V, Boyle ME, Harris JK, Magallanez JM, Littman SD. Inpatient to outpatient transfer of diabetes care: planing for an effective hospital discharge. Endocr Pract. 2009 Apr;15(3):263-9. Review.</citation>
    <PMID>19364697</PMID>
  </reference>
  <reference>
    <citation>Dungan K, Lyons S, Manu K, Kulkarni M, Ebrahim K, Grantier C, Harris C, Black D, Schuster D. An individualized inpatient diabetes education and hospital transition program for poorly controlled hospitalized patients with diabetes. Endocr Pract. 2014 Dec;20(12):1265-73. doi: 10.4158/EP14061.OR.</citation>
    <PMID>25100371</PMID>
  </reference>
  <reference>
    <citation>Wexler DJ, Beauharnais CC, Regan S, Nathan DM, Cagliero E, Larkin ME. Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge. Diabetes Res Clin Pract. 2012 Nov;98(2):249-56. doi: 10.1016/j.diabres.2012.09.016. Epub 2012 Oct 1.</citation>
    <PMID>23036785</PMID>
  </reference>
  <reference>
    <citation>Kimmel B, Sullivan MM, Rushakoff RJ. Survey on transition from inpatient to outpatient for patients on insulin: what really goes on at home? Endocr Pract. 2010 Sep-Oct;16(5):785-91. doi: 10.4158/EP10013.OR.</citation>
    <PMID>20350914</PMID>
  </reference>
  <reference>
    <citation>Wheeler K, Crawford R, McAdams D, Robinson R, Dunbar VG, Cook CB. Inpatient to outpatient transfer of diabetes care: perceptions of barriers to postdischarge followup in urban African American patients. Ethn Dis. 2007 Spring;17(2):238-43.</citation>
    <PMID>17682352</PMID>
  </reference>
  <reference>
    <citation>Dungan KM. The effect of diabetes on hospital readmissions. J Diabetes Sci Technol. 2012 Sep 1;6(5):1045-52. Review.</citation>
    <PMID>23063030</PMID>
  </reference>
  <reference>
    <citation>Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization. Endocr Pract. 2012 Sep-Oct;18(5):651-9. doi: 10.4158/EP11314.OR.</citation>
    <PMID>22440990</PMID>
  </reference>
  <reference>
    <citation>Rodriguez A, Magee M, Ramos P, Seley JJ, Nolan A, Kulasa K, Caudell KA, Lamb A, MacIndoe J, Maynard G. Best Practices for Interdisciplinary Care Management by Hospital Glycemic Teams: Results of a Society of Hospital Medicine Survey Among 19 U.S. Hospitals. Diabetes Spectr. 2014 Aug;27(3):197-206. doi: 10.2337/diaspect.27.3.197.</citation>
    <PMID>26246780</PMID>
  </reference>
  <reference>
    <citation>Wright A, Feblowitz JC, Pang JE, Carpenter JD, Krall MA, Middleton B, Sittig DF. Use of order sets in inpatient computerized provider order entry systems: a comparative analysis of usage patterns at seven sites. Int J Med Inform. 2012 Nov;81(11):733-45. doi: 10.1016/j.ijmedinf.2012.04.003. Epub 2012 Jul 18.</citation>
    <PMID>22819199</PMID>
  </reference>
  <reference>
    <citation>Neinstein A, MacMaster HW, Sullivan MM, Rushakoff R. A detailed description of the implementation of inpatient insulin orders with a commercial electronic health record system. J Diabetes Sci Technol. 2014 Jul;8(4):641-51. doi: 10.1177/1932296814536290. Epub 2014 May 25. Review.</citation>
    <PMID>24876450</PMID>
  </reference>
  <reference>
    <citation>Yu CH, Sun XH, Nisenbaum R, Halapy H. Insulin order sets improve glycemic control and processes of care. Am J Med. 2012 Sep;125(9):922-8.e4. doi: 10.1016/j.amjmed.2012.02.018. Epub 2012 Jul 14.</citation>
    <PMID>22800878</PMID>
  </reference>
  <reference>
    <citation>Noschese M, Donihi AC, Koerbel G, Karslioglu E, Dinardo M, Curll M, Korytkowski MT. Effect of a diabetes order set on glycaemic management and control in the hospital. Qual Saf Health Care. 2008 Dec;17(6):464-8. doi: 10.1136/qshc.2006.021790.</citation>
    <PMID>19064664</PMID>
  </reference>
  <reference>
    <citation>Schnipper JL, Liang CL, Ndumele CD, Pendergrass ML. Effects of a computerized order set on the inpatient management of hyperglycemia: a cluster-randomized controlled trial. Endocr Pract. 2010 Mar-Apr;16(2):209-18. doi: 10.4158/EP09262.OR.</citation>
    <PMID>20061280</PMID>
  </reference>
  <reference>
    <citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.</citation>
    <PMID>18784090</PMID>
  </reference>
  <reference>
    <citation>Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med 342:381-9, 2000. Surv Ophthalmol. 2001 Mar-Apr;45(5):459-60.</citation>
    <PMID>11274700</PMID>
  </reference>
  <reference>
    <citation>Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008 Jan;31(1):81-6. Epub 2007 Oct 12.</citation>
    <PMID>17934153</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.</citation>
    <PMID>18308683</PMID>
  </reference>
  <reference>
    <citation>Krop JS, Powe NR, Weller WE, Shaffer TJ, Saudek CD, Anderson GF. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care. Diabetes Care. 1998 May;21(5):747-52.</citation>
    <PMID>9589235</PMID>
  </reference>
  <reference>
    <citation>Calver J, Brameld KJ, Preen DB, Alexia SJ, Boldy DP, McCaul KA. High-cost users of hospital beds in Western Australia: a population-based record linkage study. Med J Aust. 2006 Apr 17;184(8):393-7.</citation>
    <PMID>16618238</PMID>
  </reference>
  <reference>
    <citation>Johansen H, Nair C, Bond J. Who goes to the hospital? An investigation of high users of hospital days. Health Rep. 1994;6(2):253-77. English, French.</citation>
    <PMID>7873720</PMID>
  </reference>
  <reference>
    <citation>Zook CJ, Moore FD. High-cost users of medical care. N Engl J Med. 1980 May 1;302(18):996-1002.</citation>
    <PMID>6767975</PMID>
  </reference>
  <reference>
    <citation>Howell S, Coory M, Martin J, Duckett S. Using routine inpatient data to identify patients at risk of hospital readmission. BMC Health Serv Res. 2009 Jun 9;9:96. doi: 10.1186/1472-6963-9-96.</citation>
    <PMID>19505342</PMID>
  </reference>
  <reference>
    <citation>Shipton S. Risk factors associated with multiple hospital readmissions. Home Care Provid. 1996 Mar-Apr;1(2):83-5. Review.</citation>
    <PMID>9157913</PMID>
  </reference>
  <reference>
    <citation>Jacob L, Poletick EB. Systematic review: predictors of successful transition to community-based care for adults with chronic care needs. Care Manag J. 2008;9(4):154-65. Review.</citation>
    <PMID>19177973</PMID>
  </reference>
  <reference>
    <citation>Bersoux S, Cook CB, Kongable GL, Shu J. Trends in glycemic control over a 2-year period in 126 US hospitals. J Hosp Med. 2013 Mar;8(3):121-5. doi: 10.1002/jhm.1997. Epub 2012 Dec 19.</citation>
    <PMID>23255411</PMID>
  </reference>
  <reference>
    <citation>Shepperd S, McClaran J, Phillips CO, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000313. doi: 10.1002/14651858.CD000313.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD000313.</citation>
    <PMID>20091507</PMID>
  </reference>
  <reference>
    <citation>Robbins JM, Webb DA. Diagnosing diabetes and preventing rehospitalizations: the urban diabetes study. Med Care. 2006 Mar;44(3):292-6.</citation>
    <PMID>16501402</PMID>
  </reference>
  <reference>
    <citation>Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009 May-Jun;15(4):353-69. doi: 10.4158/EP09102.RA.</citation>
    <PMID>19454396</PMID>
  </reference>
  <reference>
    <citation>Umpierrez GE, Reyes D, Smiley D, Hermayer K, Khan A, Olson DE, Pasquel F, Jacobs S, Newton C, Peng L, Fonseca V. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care. 2014 Nov;37(11):2934-9. doi: 10.2337/dc14-0479. Epub 2014 Aug 28.</citation>
    <PMID>25168125</PMID>
  </reference>
  <reference>
    <citation>Varroud-Vial M. Improving diabetes management with electronic medical records. Diabetes Metab. 2011 Dec;37 Suppl 4:S48-52. doi: 10.1016/S1262-3636(11)70965-X. Review.</citation>
    <PMID>22208710</PMID>
  </reference>
  <reference>
    <citation>Weber V, Bloom F, Pierdon S, Wood C. Employing the electronic health record to improve diabetes care: a multifaceted intervention in an integrated delivery system. J Gen Intern Med. 2008 Apr;23(4):379-82. doi: 10.1007/s11606-007-0439-2.</citation>
    <PMID>18373133</PMID>
  </reference>
  <reference>
    <citation>Schnipper JL, Hamann C, Ndumele CD, Liang CL, Carty MG, Karson AS, Bhan I, Coley CM, Poon E, Turchin A, Labonville SA, Diedrichsen EK, Lipsitz S, Broverman CA, McCarthy P, Gandhi TK. Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: a cluster-randomized trial. Arch Intern Med. 2009 Apr 27;169(8):771-80. doi: 10.1001/archinternmed.2009.51.</citation>
    <PMID>19398689</PMID>
  </reference>
  <reference>
    <citation>Moore P, Armitage G, Wright J, Dobrzanski S, Ansari N, Hammond I, Scally A. Medicines reconciliation using a shared electronic health care record. J Patient Saf. 2011 Sep;7(3):148-54. doi: 10.1097/PTS.0b013e31822c5bf9.</citation>
    <PMID>21857238</PMID>
  </reference>
  <reference>
    <citation>Kramer JS, Hopkins PJ, Rosendale JC, Garrelts JC, Hale LS, Nester TM, Cochran P, Eidem LA, Haneke RD. Implementation of an electronic system for medication reconciliation. Am J Health Syst Pharm. 2007 Feb 15;64(4):404-22. Erratum in: Am J Health Syst Pharm. 2007 Apr 1;64(7):684.</citation>
    <PMID>17299180</PMID>
  </reference>
  <reference>
    <citation>Staroselsky M, Volk LA, Tsurikova R, Newmark LP, Lippincott M, Litvak I, Kittler A, Wang T, Wald J, Bates DW. An effort to improve electronic health record medication list accuracy between visits: patients' and physicians' response. Int J Med Inform. 2008 Mar;77(3):153-60. Epub 2007 Apr 16.</citation>
    <PMID>17434337</PMID>
  </reference>
  <reference>
    <citation>Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007 Sep;30(9):2181-6. Epub 2007 May 18.</citation>
    <PMID>17513708</PMID>
  </reference>
  <reference>
    <citation>Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 Feb;94(2):564-9. doi: 10.1210/jc.2008-1441. Epub 2008 Nov 18.</citation>
    <PMID>19017758</PMID>
  </reference>
  <reference>
    <citation>Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014 Jun;16(6):483-91. doi: 10.1111/dom.12219. Epub 2013 Oct 31. Review.</citation>
    <PMID>24118819</PMID>
  </reference>
  <reference>
    <citation>Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014 Sep;16(9):873-6. doi: 10.1111/dom.12283. Epub 2014 Mar 24.</citation>
    <PMID>24571126</PMID>
  </reference>
  <reference>
    <citation>Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014 Oct;37(10):2755-62. doi: 10.2337/dc14-0991. Epub 2014 Jul 30.</citation>
    <PMID>25078900</PMID>
  </reference>
  <reference>
    <citation>Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014 Dec;37(12):3235-43. doi: 10.2337/dc14-0990. Epub 2014 Sep 5.</citation>
    <PMID>25193531</PMID>
  </reference>
  <reference>
    <citation>Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.</citation>
    <PMID>25641260</PMID>
  </reference>
  <reference>
    <citation>Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, Yki-Järvinen H. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015 Sep;17(9):859-67. doi: 10.1111/dom.12485. Epub 2015 Jun 16.</citation>
    <PMID>25929311</PMID>
  </reference>
  <reference>
    <citation>Healy SJ, Black D, Harris C, Lorenz A, Dungan KM. Inpatient diabetes education is associated with less frequent hospital readmission among patients with poor glycemic control. Diabetes Care. 2013 Oct;36(10):2960-7. doi: 10.2337/dc13-0108. Epub 2013 Jul 8.</citation>
    <PMID>23835695</PMID>
  </reference>
  <reference>
    <citation>Mistry R, Rosansky J, McGuire J, McDermott C, Jarvik L; UPBEAT Collaborative Group. Social isolation predicts re-hospitalization in a group of older American veterans enrolled in the UPBEAT Program. Unified Psychogeriatric Biopsychosocial Evaluation and Treatment. Int J Geriatr Psychiatry. 2001 Oct;16(10):950-9.</citation>
    <PMID>11607938</PMID>
  </reference>
  <reference>
    <citation>Anderson ES, Winett RA, Wojcik JR. Self-regulation, self-efficacy, outcome expectations, and social support: social cognitive theory and nutrition behavior. Ann Behav Med. 2007 Nov-Dec;34(3):304-12.</citation>
    <PMID>18020940</PMID>
  </reference>
  <reference>
    <citation>Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess. 1990 Winter;55(3-4):610-7.</citation>
    <PMID>2280326</PMID>
  </reference>
  <reference>
    <citation>Mitchell SE, Sadikova E, Jack BW, Paasche-Orlow MK. Health literacy and 30-day postdischarge hospital utilization. J Health Commun. 2012;17 Suppl 3:325-38. doi: 10.1080/10810730.2012.715233.</citation>
    <PMID>23030580</PMID>
  </reference>
  <reference>
    <citation>Weiss BD, Mays MZ, Martz W, Castro KM, DeWalt DA, Pignone MP, Mockbee J, Hale FA. Quick assessment of literacy in primary care: the newest vital sign. Ann Fam Med. 2005 Nov-Dec;3(6):514-22. Erratum in: Ann Fam Med. 2006 Jan-Feb;4(1):83.</citation>
    <PMID>16338915</PMID>
  </reference>
  <reference>
    <citation>Anderson RM, Fitzgerald JT, Gruppen LD, Funnell MM, Oh MS. The Diabetes Empowerment Scale-Short Form (DES-SF). Diabetes Care. 2003 May;26(5):1641-2.</citation>
    <PMID>12716841</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Oakes JM, Feldman HA. Statistical power for nonequivalent pretest-posttest designs. The impact of change-score versus ANCOVA models. Eval Rev. 2001 Feb;25(1):3-28.</citation>
    <PMID>11205523</PMID>
  </reference>
  <reference>
    <citation>International Hypoglycaemia Study Group. Erratum to: Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2017 Feb;60(2):377. doi: 10.1007/s00125-016-4168-0.</citation>
    <PMID>27921135</PMID>
  </reference>
  <reference>
    <citation>Mehrotra DV, Li X, Liu J, Lu K. Analysis of longitudinal clinical trials with missing data using multiple imputation in conjunction with robust regression. Biometrics. 2012 Dec;68(4):1250-9. doi: 10.1111/j.1541-0420.2012.01780.x. Epub 2012 Sep 20.</citation>
    <PMID>22994905</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kathleen Dungan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

